Jodi K Maranchie
Overview
Explore the profile of Jodi K Maranchie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1687
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Wiley H, Srinivasan R, Maranchie J, Chhablani J, Bondergaard Iversen A, Kruse A, et al.
Ophthalmology
. 2025 Feb;
132(3):374.
PMID: 39986707
No abstract available.
3.
Berg S, La Rosa S, Zhang T, Pierorazio P, Albiges L, Beckermann K, et al.
Urol Oncol
. 2024 Nov;
43(3):135-146.
PMID: 39500687
Modern advances in systemic and localized therapies for patients with renal cell carcinoma (RCC) have significantly improved patients' outcomes. If disease progression occurs after initial treatment, clinicians often have multiple...
4.
Iliopoulos O, Iversen A, Narayan V, Maughan B, Beckermann K, Oudard S, et al.
Lancet Oncol
. 2024 Sep;
25(10):1325-1336.
PMID: 39284337
Background: The first-in-class hypoxia-inducible factor-2α inhibitor, belzutifan, showed clinically meaningful antitumour activity in von Hippel-Lindau (VHL) disease-associated neoplasms in the ongoing, single-arm, phase 2 LITESPARK-004 study. We aimed to investigate...
5.
Wiley H, Srinivasan R, Maranchie J, Chhablani J, Bondergaard Iversen A, Kruse A, et al.
Ophthalmology
. 2024 Jun;
131(11):1324-1332.
PMID: 38849055
Purpose: To report the efficacy of the oral hypoxia-inducible factor 2α inhibitor belzutifan in participants with von Hippel-Lindau disease-associated retinal hemangioblastomas in the LITESPARK-004 study. Design: Subgroup analysis of the...
6.
Else T, Jonasch E, Iliopoulos O, Beckermann K, Narayan V, Maughan B, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1750-1757.
PMID: 38393723
Purpose: Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC) and other neoplasms with...
7.
Chrouser K, Foley F, Goldenberg M, Hyder J, Maranchie J, Moore J, et al.
Urol Pract
. 2023 Jun;
7(4):309-318.
PMID: 37317463
Introduction: Intraoperative surgical outcomes are influenced by a wide variety of patient, surgeon and institutional factors. The current literature lacks comprehensive resources that describe best practices in preventing patient safety...
8.
Turkbey B, Oto A, Allen B, Akin O, Alexander L, Ari M, et al.
J Am Coll Radiol
. 2023 May;
20(5S):S164-S186.
PMID: 37236741
Prostate cancer has a wide spectrum ranging between low-grade localized disease and castrate-resistant metastatic disease. Although whole gland and systematic therapies result in cure in the majority of patients, recurrent...
9.
Schieda N, Oto A, Allen B, Akin O, Barker S, Fulgham P, et al.
J Am Coll Radiol
. 2022 May;
19(5S):S194-S207.
PMID: 35550802
The staging and surveillance of testicular cancer is a complex topic, which integrates clinical, biochemical, and imaging components. The use of imaging for staging and surveillance of testicular cancer is...
10.
Jonasch E, Donskov F, Iliopoulos O, Rathmell W, Narayan V, Maughan B, et al.
N Engl J Med
. 2021 Nov;
385(22):2036-2046.
PMID: 34818478
Background: Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α)....